Medovate is joining the Association of British HealthTech Industries (ABHI) US Accelerator 2022 cohort and is participating in the programme for a second year running.
Now in its fifth year, the ABHI US Accelerator, conducted in partnership with the Dell Medical School in Austin, Texas, supports UK medical device, diagnostic and digital health companies looking to access the US healthcare landscape.
The 12-month programme provides companies with the opportunity to define and strengthen their US strategy, de-risk market entry and grow their US business by utilising ABHI’s advice, expertise, and connections within the country.
Medovate was spun out of the NHS in 2017 and was created to identify and commercialise high potential innovations from the NHS, providing vital expertise to lead these through development, clinical trials, regulatory approval, manufacture, and market launch.
Over the next 12 months, ABHI will work with Medovate along with 39 other companies who have been successful on joining this year’s programme, to provide bespoke support, introductions, and insights specific to the US health eco-systems. UK companies in the programme will also be boosted by access to an expansive network of in-market experts.
Chris Rogers, sales & marketing director said: “The US is a strategic market for Medovate, and we are excited to be part of the US Accelerator in 2022 for the second year running.
“We are keen to build relationships with US health systems with the aim to further validate SAFIRA, our first product to be brought to market. One of our other goals is the opportunity to further develop some of the additional products we have in our portfolio. We have some phenomenal products that we believe will have real value in the United States and are looking forward to show-casing British NHS innovation stateside.”
Another key goal the company hopes to achieve through its participation in the programme, is the opportunity to further develop additional products in their portfolio.
This includes Glucosave, a patient safety solution designed to help reduce the risk of a glucose solution being erroneously attached to an arterial line and ENDOVAC which applies the principles of negative pressure wound therapy internally to holes in the Upper Gastrointestinal Tract thus removing sources of infection and promoting healing.
The 2022 ABHI US Accelerator programme will run from January 2022 – December 2022, with participants able to make full use of ABHI’s dedicated workspace and office at the Dell Medical School, with access to their facilities and support from senior faculty.
Since its establishment in 2017, the ABHI US Accelerator has led to over 25 international research collaborations and new business generated for UK industry.
The programme has been expanded over the years, and is now supporting 40 companies, several of which are longstanding members of the programme, drive their operations in the US.
Centred in Texas and using the state as a springboard to other key states, the programme offers nationwide support, drawing on the relationships and connections built up across the US.
Paul Benton, managing director, international at ABHI, said: “We are delighted that our programme continues to attract such high calibre applicants. The ABHI US Accelerator is a fantastic platform for UK healthtech innovators looking to access the US healthcare landscape. In helping companies to de-risk US market entry, it also acts as a catalyst for growth, offering access to senior physicians, c-suite level health system executives, payers, and a broad network of US healthcare contacts. We look forward to supporting each company in their goal to grow and develop within one of the world's largest healthtech markets.”
